Linked Life Data

12570694

Source:http://linkedlifedata.com/resource/pubmed/id/12570694

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2003-2-6
pubmed:abstractText
In cells, protein degradation is a key pathway for the destruction of abnormal or damaged proteins as well as for the elimination of proteins whose presence is no longer required. Among the various cell proteases, the proteasome, a multicatalytic macromolecular complex, is specifically required for the degradation of ubiquitinated proteins. In normal cells, the proteasome ensures the elimination of numerous proteins that play critical roles in cell functions throughout the cell cycle. Defects in the activity of this proteolytic machinery can lead to the disorders of cell function that is believed to be the root cause of certain diseases. Indeed, many proteins involved in the control of cell cycle transitions are readily destroyed by the proteasome once their tasks have been accomplished. Moreover, because proteasome inhibitors can provoke cell death, it has been suggested that proteasomes must be continually degrading certain apoptotic factors. For these reasons, proteasome inhibition has become a new and potentially significant strategy for the drug development in cancer treatment. The proteasome possesses three major peptidase activities that can individually be targeted by drugs. Different classes of proteasome inhibitors are reviewed here. In addition, we present new pseudopeptides with the enriched nitrogen backbones bearing a side chain and a modified C-terminal position that inhibit proteasome activity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0929-8673
pubmed:author
pubmed:issnType
Print
pubmed:volume
10
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
479-503
pubmed:dateRevised
2007-2-12
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Proteasome inhibitors as therapeutic agents: current and future strategies.
pubmed:affiliation
Groupe Cycle Cellulaire, CNRS UMR 6061 Génétique et Développement, IFR 97 Génomique Fonctionnelle et Santé, Faculté de Médecine, Université Rennes 1, 2 av du Pr Léon Bernard, CS 34317, 35043 Rennes Cedex, France.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't